Andere Sprachen Pasithea Therapeutics Corp.

Aktien

A3E4YX

US70261F2020

KTTA

Markt geschlossen - Nasdaq Andere Börsenplätze 22:30:01 09.05.2024			% 5 Tage	% 1. Jan.
7.68 ^USD	+8.93%		+10.98%	+3.78%

24.04.	Pasithea Therapeutics Corp. gibt bekannt, dass die erste Kohorte die erste Dosierung in der Phase-1-Studie zur Bewertung von Pas-004 bei Ras-, Nf1- und Raf-mutierten Krebsarten abgeschlossen hat	CI
29.03.	Pasithea Therapeutics Corp. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Pasithea Therapeutics Announces PAS-004 Abstract Accepted for Poster Presentation at 2024 ASCO Annual Meeting	29.04.
Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers	24.04.
Pasithea Therapeutics Corp. Announces the First Cohort Has Completed the Initial Dosing in Its Phase 1 Trial Evaluating Pas-004 in Ras, Nf1 and Raf Mutated Cancers	24.04.
Pasithea Therapeutics Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	29.03.
Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for its Phase 1 Trial of PAS-004	13.02.
Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for Its Phase 1 Trial of Pas-004	13.02.
Top Premarket Decliners	12.01.
Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004, Establishes Strengthened Intellectual Property Position	09.01.
Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) Position	08.01.
Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) Position	08.01.
Pasithea Therapeutics Shares Rise on FDA Clearance to Evaluate PAS-004 in Advanced Cancer Patients	02.01.
Pasithea Therapeutics Gets FDA Acceptance for PAS-004 IND Application	02.01.
Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients	02.01.
Pasithea Therapeutics Corp. Announces FDA Acceptance of Ind Application to Evaluate Pas-004 in Advanced Cancer Patients	02.01.
Pasithea Therapeutics Announces Adjournment of Reconvened Meeting of Stockholders to December 29, 2023	28.12.
Pasithea Therapeutics Announces Results from 2023 Annual Meeting	19.12.
Wall Street Set to Open Slightly Higher Tuesday; Annual Inflation Declines to 3.1%	12.12.
Pasithea Therapeutics Announces Positive In Vivo Preclinical Efficacy Data for PAS-004 from NRAS Mutation Cancer Xenograft Models	11.12.
Pasithea Therapeutics Announces Adjournment of 2023 Annual Meeting of Stockholders	29.11.
Pasithea Therapeutics Gets Positive Response From FDA Meeting for Rare Cancer Treatment	29.11.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Pasithea Therapeutics Corp.

Aktien

A3E4YX

US70261F2020

KTTA

Andere Sprachen

Filter